Identifying predictors, moderators, and mediators of antidepressant response in major depressive disorder: Neuroimaging approaches

American Journal of Psychiatry

Volumn 172, Issue 2, 2015, Pages 124-138

  Phillips, Mary L ^a,b,c,d,e   Chase, Henry W ^a,b,c,d,e   Sheline, Yvette I ^a,b,c,d,e   Etkin, Amit ^a,b,c,d,e   Almeida, Jorge R C ^a,b,c,d,e   Deckersbach, Thilo ^a,b,c,d,e   Trivedi, Madhukar H ^a,b,c,d,e  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; CLOMIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; KETAMINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

AMYGDALOID NUCLEUS; CORPUS STRIATUM; DIFFUSION TENSOR IMAGING; DOPAMINERGIC SYSTEM; DRUG RESPONSE; EMOTIONALITY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MAJOR DEPRESSION; MULTIMODAL IMAGING; NERVE CELL NETWORK; NEUROIMAGING; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREFRONTAL CORTEX; REVIEW; REWARD; SAMPLE SIZE; SEROTONINERGIC SYSTEM; SPIN LABELING; BRAIN; DEPRESSIVE DISORDER, MAJOR; METABOLISM; PATHOLOGY; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME; TRENDS;

ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; BRAIN; DEPRESSIVE DISORDER, MAJOR; HUMANS; NEUROIMAGING; NEUROTRANSMITTER AGENTS; PROGNOSIS; TREATMENT OUTCOME;

EID: 84922241944     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2014.14010076     Document Type: Review

References (184)

1. Collins PY, Patel V, Joestl SS, et al: Grand challenges in global mental health. Nature 2011; 475:27-30
2. Kupfer DJ, Frank E, Phillips ML: Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet 2012; 379:1045-1055
3. Phillips ML, Swartz HA: A critical appraisal of neuroimaging studies of bipolar disorder: toward a new conceptualization of underlyingneuralcircuitryandaroadmap for futureresearch. Am J Psychiatry 2014; 171:829-843
4. Trivedi MH, Rush AJ, Wisniewski SR, et al: Evaluation ofoutcomes with citalopram for depression using measurement-based care in STAR∗D: implications for clinical practice. Am J Psychiatry 2006; 163:28-40
5. Phillips ML, Kupfer DJ: Bipolar disorder diagnosis: challenges and future directions. Lancet 2013; 381:1663-1671
6. Mayberg HS, Brannan SK, Tekell JL, et al: Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 2000; 48:830-843
7. Kumar P, Waiter G, Ahearn T, et al: Abnormal temporal difference reward-learning signals in major depression. Brain 2008; 131:2084-2093
8. Pizzagalli DA: Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology 2011; 36:183-206
9. Chase HW, Nusslock R, Almeida JR, et al: Dissociable patterns of abnormal frontal cortical activation during anticipation of an uncertain reward or loss in bipolar versus major depression. Bipolar Disord 2013; 15:839-854
10. Pizzagalli DA, Holmes AJ, Dillon DG, et al: Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. Am J Psychiatry 2009; 166:702-710
11. Keedwell PA, Andrew C, Williams SC, et al: The neural correlates of anhedonia in major depressive disorder. Biol Psychiatry 2005; 58: 843-853
12. Insel T, Cuthbert B, Garvey M, et al: Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 2010; 167:748-751
13. Phillips ML, Ladouceur CD, Drevets WC: A neural model of voluntary and automatic emotion regulation: implications for understanding the pathophysiology and neurodevelopment of bipolar disorder. Mol Psychiatry 2008; 13:833-857
14. Jasinska AJ, Lowry CA, Burmeister M: Serotonin transporter gene, stress, and raphe-raphe interactions: a molecular mechanism of depression. Trends Neurosci 2012; 35:395-402
15. Klucken T, Wehrum S, Schweckendiek J, et al: The 5-HTTLPR polymorphism is associated with altered hemodynamic responses during appetitive conditioning. Hum Brain Mapp 2013; 34:2549-2560
16. Volman I, Verhagen L, den Ouden HE, et al: Reduced serotonin transporter availability decreases prefrontal control of the amygdala. J Neurosci 2013; 33:8974-8979
17. Hariri AR, Mattay VS, Tessitore A, et al: Serotonin transporter genetic variation and the response of the human amygdala. Science 2002; 297:400-403
18. Pezawas L, Meyer-Lindenberg A, Drabant EM, et al: 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci 2005; 8:828-834
19. Dannlowski U, Konrad C, Kugel H, et al: Emotion specific modulation of automatic amygdala responses by 5-HTTLPR genotype. Neuroimage 2010; 53:893-898
20. Outhred T, Hawkshead BE, Wager TD, et al: Acute neural effects of selective serotonin reuptake inhibitors versus noradrenaline reuptake inhibitors on emotion processing: implications for differential treatment efficacy. Neurosci Biobehav Rev 2013; 37:1786-1800
21. Grady CL, Siebner HR, Hornboll B, et al: Acute pharmacologically induced shifts in serotonin availability abolish emotion-selective responses to negative face emotions in distinct brain networks. Eur Neuropsychopharmacol 2013; 23:368-378
22. McCabe C, Mishor Z, Cowen PJ, et al: Diminished neural pro-cessingof aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biol Psychiatry 2010; 67:439-445
23. Windischberger C, Lanzenberger R, Holik A, et al: Area-specific modulation of neural activation comparing escitalopram and cit-alopram revealed by pharmaco-fMRI: a randomized cross-over study. Neuroimage 2010; 49:1161-1170
24. Murphy SE, Norbury R, O'Sullivan U, et al: Effect of a single dose of citalopram on amygdala response to emotional faces. Br J Psychiatry 2009; 194:535-540
25. Anderson IM, Del-Ben CM, Mckie S, et al: Citalopram modulation of neronal responses to aversive face emotions: a functional MRI study. Neuroreport 2007; 18:1351-1355
26. Harmer CJ, Mackay CE, Reid CB, et al: Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol Psychiatry 2006; 59:816-820
27. van Marle HJ, Tendolkar I, Urner M, et al: Subchronic duloxetine administration alters the extended amygdala circuitry in healthy individuals. Neuroimage 2011; 55:825-831
28. Robinson OJ, Overstreet C, Allen PS, et al: The role of serotonin in the neurocircuitry of negative affective bias: serotonergic modulation of the dorsal medial prefrontal-amygdala "aversive amplification" circuit. Neuroimage 2013; 78:217-223
29. Passamonti L, Crockett MJ, Apergis-Schoute AM, et al: Effects of acute tryptophan depletion on prefrontal-amygdala connectivity while viewing facial signals of aggression. Biol Psychiatry 2012; 71: 36-43
30. de Almeida JR, Phillips ML, Cerqueira CT, et al: Neural activity changes to emotional stimuli in healthy individuals under chronic use of clomipramine. J Psychopharmacol 2010; 24:1165-1174
31. Bigos KL, Pollock BG, Aizenstein HJ, et al: Acute 5-HT reuptake blockade potentiates human amygdala reactivity. Neuropsychopharmacology 2008; 33:3221-3225
32. Di Simplicio M, Norbury R, Reinecke A, et al: Paradoxical effects of short-term antidepressant treatment in fMRI emotional processing models in volunteers with high neuroticism. Psychol Med 2014; 44: 241-252
33. Rhodes RA, Murthy NV, Dresner MA, et al: Human 5-HT transporter availability predicts amygdala reactivity in vivo. J Neurosci 2007; 27:9233-9237
34. Fisher PM, Meltzer CC, Price JC, et al: Medial prefrontal cortex 5-HT(2A) density is correlated with amygdala reactivity, response habituation, and functional coupling. Cereb Cortex 2009; 19:2499-2507
35. Stjepanovic D, Lorenzetti V, Yücel M, et al: Human amygdala volume is predicted by common DNA variation in the stathmin and serotonin transporter genes. Transl Psychiatr 2013; 3:e283
36. Kobiella A, Reimold M, Ulshöfer DE, et al: How the serotonin transporter 5-HTTLPR polymorphism influences amygdala function: the roles of in vivo serotonin transporter expression and amygdala structure. Transl Psychiatr 2011; 1:e37
37. Inoue H, Yamasue H, Tochigi M, et al: Effect of tryptophan hydroxylase-2 gene variants on amygdalar and hippocampal volumes. Brain Res 2010; 1331:51-57
38. Surguladze SA, Radua J, El-Hage W, et al: Interaction of catechol O-methyltransferase and serotonin transporter genes modulates effective connectivity in a facial emotion-processing circuitry. Transl Psychiatr 2012; 2:e70
39. Domschke K, Baune BT, Havlik L, et al: Catechol-O-methyltransferase gene variation: impact on amygdala response to aversive stimuli. Neuroimage 2012; 60:2222-2229
40. Dayan P, Balleine BW: Reward, motivation, and reinforcement learning. Neuron 2002; 36:285-298
41. Schultz W: Multiple dopamine functions at different time courses. Annu Rev Neurosci 2007; 30:259-288
42. Takahashi YK, Roesch MR, Wilson RC, et al: Expectancy-related changes in firing of dopamine neurons depend on orbitofrontal cortex. Nat Neurosci 2011; 14:1590-1597
43. Gradin VB, Kumar P, Waiter G, et al: Expected value and prediction error abnormalities in depression and schizophrenia. Brain 2011; 134:1751-1764
44. Wise RA: Dopamine, learning, and motivation. Nat Rev Neurosci 2004; 5:483-494
45. Beckmann M, Johansen-Berg H, Rushworth MF: Connectivity-based parcellation of human cingulate cortex and its relation to functional specialization. J Neurosci 2009; 29:1175-1190
46. Ongür D, Price JL: The organization of networks within the orbital and medial prefrontal cortex of rats, monkeys, and humans. Cereb Cortex 2000; 10:206-219
47. Ernst M, Nelson EE, McClure EB, et al: Choice selection and reward anticipation: an fMRI study. Neuropsychologia 2004; 42:1585-1597
48. Rogers RD, Ramnani N, Mackay C, et al: Distinct portions of anterior cingulate cortex and medial prefrontal cortex are activated by reward processing in separable phases of decision-making cognition. Biol Psychiatry 2004; 55:594-602
49. Lawrence NS, Jollant F, O'Daly O, et al: Distinct roles of prefrontal cortical subregions in the Iowa Gambling Task. Cereb Cortex 2009; 19:1134-1143
50. Dillon DG, Holmes AJ, Jahn AL, et al: Dissociation of neural regions associated with anticipatory versus consummatory phases of incentive processing. Psychophysiology 2008; 45:36-49
51. Pedroni A, Koeneke S, Velickaite A, et al: Differential magnitude coding of gains and omitted rewards in the ventral striatum. Brain Res 2011; 1411:76-86
52. Haber SN, Knutson B: The reward circuit: linking primate anatomy and human imaging. Neuropsychopharmacology 2010; 35:4-26
53. Grabenhorst F, Rolls ET: Value, pleasure, and choice in the ventral prefrontal cortex. Trends Cogn Sci 2011; 15:56-67
54. Forbes EE, Brown SM, Kimak M, et al: Genetic variation in components of dopamine neurotransmission impacts ventral striatal reactivity associated with impulsivity. Mol Psychiatry 2009; 14:60-70
55. Schott BH, Minuzzi L, Krebs RM, et al: Mesolimbic functional magnetic resonance imagingactivations during rewardanticipation correlate with reward-related ventral striatal dopamine release. J Neurosci 2008; 28:14311-14319
56. Buckholtz JW, Treadway MT, Cowan RL, et al: Dopaminergic network differences in human impulsivity. Science 2010; 329:532
57. Ceccarini J, Vrieze E, Koole M, et al: Optimizedin vivo detection of dopamine release using 18F-fallypride PET. J Nucl Med 2012; 53: 1565-1572
58. Tremblay LK, Naranjo CA, Graham SJ, et al: Functional neuro-anatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe. Arch Gen Psychiatry 2005; 62:1228-1236
59. Pessiglione M, Seymour B, Flandin G, et al: Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans. Nature 2006; 442:1042-1045
60. Ossewaarde L, Verkes RJ, Hermans EJ, et al: Two-week administration of the combined serotonin-noradrenaline reuptake inhibitor duloxetine augments functioning of mesolimbic incentive processing circuits. Biol Psychiatry 2011; 70:568-574
61. Koob GF, Le Moal M: Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001; 24:97-129
62. Biswal B, Yetkin FZ, Haughton VM, et al: Functional connectivity in the motor cortex of resting human brain using echo-planar MRI. Magn Reson Med 1995; 34:537-541
63. Fox MD, Raichle ME: Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci 2007; 8:700-711
64. Greicius MD, Flores BH, Menon V, et al: Resting-state functional connectivity in major depression: abnormally increased contribu-tionsfromsubgenual cingulatecortexandthalamus. Biol Psychiatry 2007; 62:429-437
65. Buckner RL, Krienen FM, Yeo BT: Opportunities and limitations of intrinsic functionalconnectivityMRI. Nat Neurosci 2013; 16:832-837
66. Murphy K, Birn RM, Bandettini PA: Resting-state fMRI confounds and cleanup. Neuroimage 2013; 80:349-359
67. Honey CJ, Sporns O, Cammoun L, et al: Predicting human resting-state functional connectivity from structural connectivity. Proc Natl Acad Sci USA 2009; 106:2035-2040
68. Shirer WR, Ryali S, Rykhlevskaia E, et al: Decoding subject-driven cognitive states with whole-brain connectivity patterns. Cereb Cortex 2012; 22:158-165
69. Deco G, Jirsa VK, McIntosh AR: Emerging concepts for the dynamical organization of resting-state activity in the brain. Nat Rev Neurosci 2011; 12:43-56
70. Hutchison RM, Womelsdorf T, Allen EA, et al: Dynamic functional connectivity: promise, issues, and interpretations. Neuroimage 2013; 80:360-378
71. Greicius MD, Krasnow B, Reiss AL, et al: Functional connectivity in the resting brain:anetwork analysisofthe default mode hypothesis. Proc Natl Acad Sci USA 2003; 100:253-258
72. Fox MD, Snyder AZ, Vincent JL, et al: The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proc Natl Acad Sci USA 2005; 102:9673-9678
73. Andrews-Hanna JR, Reidler JS, et al: Functional-anatomic frac-tionation of the brain's default network. Neuron 2010; 65:550-562
74. Fox MD, Corbetta M, Snyder AZ, et al: Spontaneous neuronal activity distinguishes human dorsal and ventral attention systems. Proc Natl Acad Sci USA 2006; 103:10046-10051
75. Vincent JL, Snyder AZ, Fox MD, et al: Coherent spontaneous activity identifies a hippocampal-parietal memory network. J Neurophysiol 2006; 96:3517-3531
76. Damoiseaux JS, Rombouts SA, Barkhof F, et al: Consistent resting-state networks across healthy subjects. Proc Natl Acad Sci USA 2006; 103:13848-13853
77. Seeley WW, Menon V, Schatzberg AF, et al: Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci 2007; 27:2349-2356
78. Etkin A, Prater KE, Schatzberg AF, et al: Disrupted amygdalar subregion functional connectivity and evidence of a compensatory networkingeneralizedanxietydisorder. ArchGen Psychiatry 2009; 66:1361-1372
79. Aslan S, Lu H: On the sensitivity of ASL MRI in detecting regional differences in cerebral blood flow. Magn Reson Imaging 2010; 28: 928-935
80. Ye FQ, Berman KF, Ellmore T, et al: H(2)(15)O PET validation of steady-state arterial spin tagging cerebralbloodflow measurements in humans. Magn Reson Med 2000; 44:450-456
81. Mori S, Zhang J: Principles of diffusion tensor imaging and its applications to basic neuroscience research. Neuron 2006; 51:527-539
82. Versace A, Andreazza AC, Young LT, et al: Elevated serum measures of lipid peroxidation and abnormal prefrontal white matterin euthymic bipolar adults: toward peripheral biomarkers of bipolar disorder. Mol Psychiatry 2014; 19:200-208
83. Delvecchio G, Fossati P, Boyer P, et al: Common and distinct neural correlates of emotional processing in bipolar disorder and major depressive disorder: a voxel-based meta-analysis of functional magnetic resonance imaging studies. Eur Neuropsychopharmacol 2012; 22:100-113
84. Hamilton JP, Etkin A, Furman DJ, et al: Functional neuroimaging of major depressive disorder: a meta-analysis and new integration of baseline activation and neural response data.Am J Psychiatry 2012; 169:693-703
85. Almeida JR, Versace A, Mechelli A, et al: Abnormal amygdala-prefrontal effective connectivity to happy faces differentiates bipolar from major depression. Biol Psychiatry 2009; 66:451-459
86. Anand A, Li Y, Wang Y, et al: Reciprocal effects of antidepressant treatment on activity and connectivity of the mood regulating circuit: an fMRI study. J Neuropsychiatry Clin Neurosci 2007; 19: 274-282
87. Fu CH, Williams SC, Cleare AJ, et al: Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch Gen Psychiatry 2004; 61:877-889
88. Sheline YI, Barch DM, Donnelly JM, et al: Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment:anfMRI study. Biol Psychiatry2001; 50:651-658
89. Victor TA, Furey ML, Fromm SJ, et al: Relationship between amygdala responses to masked faces and mood state and treatment in major depressive disorder. Arch Gen Psychiatry 2010; 67: 1128-1138
90. Davey CG, Allen NB, Harrison BJ, et al: Increased amygdala response to positive social feedback in young people with major depressive disorder. Biol Psychiatry 2011; 69:734-741
91. Moses-Kolko EL, Perlman SB, Wisner KL, et al: Abnormally reduced dorsomedial prefrontal cortical activity and effective connectivity with amygdala in response to negative emotional faces in postpartum depression. Am J Psychiatry 2010; 167:1373-1380
92. Suslow T, Konrad C, Kugel H, et al: Automatic mood-congruent amygdala responses to masked facial expressions in major depression. Biol Psychiatry 2010; 67:155-160
93. Victor TA, Furey ML, Fromm SJ, et al: The extended functional neuroanatomy of emotional processing biases for masked faces in major depressive disorder. PLoS ONE 2012; 7:e46439
94. Arnone D, McKie S, Elliott R, et al: Increasedamygdala responsesto sad but not fearful faces in major depression: relation to mood state and pharmacological treatment. Am J Psychiatry 2012; 169:841-850
95. Mingtian Z, Shuqiao Y, Xiongzhao Z, et al: Elevated amygdala activity to negative faces in young adults with early onset major depressive disorder. Psychiatry Res 2012; 201:107-112
96. Tao R, Calley CS, Hart J, et al: Brain activity in adolescent major depressive disorder before and after fluoxetine treatment. Am J Psychiatry 2012; 169:381-388
97. Stuhrmann A, Dohm K, Kugel H, et al: Mood-congruent amygdala responses to subliminally presented facial expressions in major depression: associations with anhedonia. J Psychiatry Neurosci 2013; 38:249-258
98. Holsen LM, Lancaster K, Klibanski A, et al: HPA-axis hormone modulation of stress response circuitry activity in women with remitted major depression. Neuroscience 2013; 250:733-742
99. Hooley JM, Gruber SA, Parker HA, et al: Cortico-limbic response to personally challenging emotional stimuli after complete recovery from depression. Psychiatry Res 2009; 172:83-91
100. Holsen LM, Spaeth SB, Lee JH, et al: Stress response circuitry hypoactivation related to hormonal dysfunction in women with major depression. J Affect Disord 2011; 131:379-387
101. Godlewska BR, Norbury R, Selvaraj S, et al: Short-term SSRI treatment normalisesamygdala hyperactivityindepressedpatients. Psychol Med 2012; 42:2609-2617
102. Robertson B, Wang L, Diaz MT, et al: Effect of bupropion extended release on negative emotion processing in major depressive disorder: a pilot functional magnetic resonance imaging study. J Clin Psychiatry 2007; 68:261-267
103. Keedwell PA, Andrew C, Williams SC, et al:Adouble dissociation of ventromedialprefrontalcorticalresponsestosadandhappystimuliin depressed and healthy individuals. Biol Psychiatry 2005; 58:495-503
104. Knutson B, Bhanji JP, Cooney RE, et al:Neuralresponsestomonetary incentives in major depression. Biol Psychiatry 2008; 63:686-692
105. Smoski MJ, Felder J, Bizzell J, et al: fMRI of alterations in reward selection, anticipation, and feedback in major depressive disorder. J Affect Disord 2009; 118:69-78
106. Heller AS, Johnstone T, Shackman AJ, et al: Reduced capacity to sustain positive emotion in major depression reflects diminished maintenance of fronto-striatal brain activation. Proc Natl Acad Sci USA 2009; 106:22445-22450
107. Harvey PO, Pruessner J, Czechowska Y, et al: Individualdifferences in trait anhedonia: a structural and functional magnetic resonance imaging study in non-clinical subjects. Mol Psychiatry 2007; 12: 767-775
108. Surguladze S, Brammer MJ, Keedwell P, et al:Adifferential pattern of neural response toward sad versus happy facial expressions in major depressive disorder. Biol Psychiatry 2005; 57:201-209
109. Robinson OJ, Cools R, Carlisi CO, et al: Ventral striatum response during reward and punishment reversal learning in unmedicated major depressive disorder. Am J Psychiatry 2012; 169:152-159
110. Moses-Kolko EL, Fraser D, Wisner KL, et al: Rapid habituation of ventral striatal response to reward receipt in postpartum depression. Biol Psychiatry 2011; 70:395-399
111. Vrieze E, Pizzagalli DA, Demyttenaere K, et al: Reduced reward learning predicts outcome in major depressive disorder. Biol Psychiatry 2013; 73:639-645
112. Dichter GS, Felder JN, Petty C, et al: The effects of psychotherapy on neural responsestorewardsinmajor depression. Biol Psychiatry 2009; 66:886-897
113. Kempton MJ, Salvador Z, Munafò MR, et al: Structural neuro-imaging studies in major depressive disorder: meta-analysis and comparison with bipolar disorder. Arch Gen Psychiatry 2011; 68: 675-690
114. Koolschijn PC, van Haren NE, Lensvelt-Mulders GJ, et al: Brain volume abnormalitiesin major depressive disorder:ameta-analysis of magnetic resonance imaging studies. Hum Brain Mapp 2009; 30: 3719-3735
115. Campbell S, Marriott M, Nahmias C, et al: Lower hippocampal volumeinpatients suffering from depression:ameta-analysis. Am J Psychiatry 2004; 161:598-607
116. Fischl B, Dale AM: Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci USA 2000; 97:11050-11055
117. Peterson BS, Warner V, Bansal R, et al: Cortical thinning in persons at increased familial risk for major depression. Proc Natl Acad Sci USA 2009; 106:6273-6278
118. Davey CG, Harrison BJ, Yucel M, et al: Regionally specific alterations in functional connectivity of the anterior cingulate cortex in major depressive disorder. Psychol Med 2012; 42:2071-2081
119. Ma C, Ding J, Li J, et al: Resting-state functional connectivity bias of middletemporalgyrus and caudate with altered gray mattervolume in major depression. PLoS ONE 2012; 7:e45263
120. Anand A, Li Y, Wang Y, et al:Activityandconnectivityofbrainmood regulating circuit in depression: a functional magnetic resonance study. Biol Psychiatry 2005; 57:1079-1088
121. Lui S, Wu Q, Qiu L, et al: Resting-state functional connectivity in treatment-resistant depression. Am J Psychiatry 2011; 168:642-648
122. Tang Y, Kong L, Wu F, et al: Decreased functional connectivity between the amygdala and the left ventral prefrontal cortex in treatment-naive patients with major depressive disorder: a resting-state functional magnetic resonance imaging study. Psychol Med 2013; 43:1921-1927
123. Cullen KR, Gee DG, Klimes-Dougan B, et al: A preliminary study of functional connectivity in comorbid adolescent depression. Neu-rosci Lett 2009; 460:227-231
124. Meng C, Brandl F, Tahmasian M, et al: Aberrant topology of striatum's connectivity isassociated with the number of episodes in depression. Brain 2014; 137:598-609
125. Sheline YI, Price JL, Yan Z, et al: Resting-state functional MRI in depression unmasks increased connectivity between networks via the dorsal nexus. Proc Natl Acad Sci USA 2010; 107:11020-11025
126. McCabe C, Mishor Z: Antidepressant medications reduce subcortical-cortical resting-state functional connectivity in healthy volunteers. Neuroimage 2011; 57:1317-1323
127. Duhameau B, Ferré JC, Jannin P, et al: Chronic and treatment-resistant depression: a study using arterial spin labeling perfusion MRI at 3 tesla. Psychiatry Res 2010; 182:111-116
128. Clark CP, Brown GG, Archibald SL, et al: Does amygdalar perfusion correlate with antidepressant response to partial sleep deprivation in major depression? Psychiatry Res 2006; 146:43-51
129. Chen Y, Wan HI, O'Reardon JP, et al: Quantification of cerebral bloodflowas biomarkerof drug effect: arterial spin labeling phMRI after a single dose of oral citalopram. Clin Pharmacol Ther 2011; 89: 251-258
130. Järnum H, Eskildsen SF, Steffensen EG, et al: Longitudinal MRI studyofcortical thickness, perfusion, and metabolitelevelsinmajor depressive disorder. Acta Psychiatr Scand 2011; 124:435-446
131. Sexton CE, Mackay CE, Ebmeier KP: A systematic review of diffusion tensor imaging studies in affective disorders. Biol Psychiatry 2009; 66:814-823
132. Zhang A, Ajilore O, Zhan L, et al: White matter tract integrity of anterior limb of internal capsule in major depression and type 2 diabetes. Neuropsychopharmacology 2013; 38:1451-1459
133. Whalley HC, Sprooten E, Hackett S, et al: Polygenic risk and white matter integrity in individuals at high risk of mood disorder. Biol Psychiatry 2013; 74:280-286
134. de Kwaasteniet B, Ruhe E, Caan M, et al: Relation between structural and functional connectivityin major depressive disorder. Biol Psychiatry 2013; 74:40-47
135. Huang H, Fan X, Williamson DE, et al: White matter changes in healthy adolescents at familial risk for unipolar depression: a diffusion tensor imaging study. Neuropsychopharmacology 2011; 36: 684-691
136. Cullen KR, Klimes-Dougan B, Muetzel R, et al: Altered white matter microstructureinadolescents with major depression:a preliminary study. J Am Acad Child Adolesc Psychiatry 2010; 49:173.e1-183.e1
137. Zhu X, Wang X, Xiao J, et al: Altered white matter integrity in first-episode treatment-naive young adults with major depressive disor-der:atract-basedspatialstatisticsstudy. Brain Res 2011; 1369:223-229
138. Huang H, Gundapuneedi T, Rao U: White matter disruptions in adolescents exposed to childhood maltreatment and vulnerability to psychopathology. Neuropsychopharmacology 2012; 37:2693-2701
139. Murphy ML, Carballedo A, Fagan AJ, et al: Neurotrophic tyrosine kinase polymorphism impacts white matter connections in patients with major depressive disorder. Biol Psychiatry 2012; 72:663-670
140. Keedwell PA, Chapman R, Christiansen K, et al: Cingulum white matter in young women at risk of depression: the effect of family history and anhedonia. Biol Psychiatry 2012; 72:296-302
141. Guo WB, Liu F, Chen JD, et al: Altered white matter integrity of forebrain in treatment-resistant depression: a diffusion tensor imaging study with tract-based spatial statistics. Prog Neuropsychopharmacol Biol Psychiatry 2012; 38:201-206
142. Carballedo A, Amico F, Ugwu I, et al: Reduced fractional anisotropy in the uncinate fasciculus in patients with major depression carrying the met-allele of the Val66Met brain-derived neurotrophic factor genotype. Am J Med Genet B Neuropsychiatr Genet 2012; 159B:537-548
143. Cole J, Chaddock CA, Farmer AE, et al: White matter abnormalities and illness severity in major depressive disorder. Br J Psychiatry 2012; 201:33-39
144. Zuo N, Fang J, Lv X, et al: White matter abnormalities in major depression: a tract-based spatial statistics and rumination study. PLoS ONE 2012; 7:e37561
145. Zhang A, Leow A, Ajilore O, et al: Quantitative tract-specific measures of uncinate and cingulum in major depression using diffusion tensor imaging. Neuropsychopharmacology 2012; 37: 959-967
146. Korgaonkar MS, Grieve SM, Koslow SH, et al: Loss of white matter integrity in major depressive disorder: evidence using tract-based spatial statistical analysis of diffusion tensor imaging. Hum Brain Mapp 2011; 32:2161-2171
147. Bezerra DM, Pereira FR, Cendes F, et al: DTI voxelwise analysis did not differentiate older depressed patients from older subjects without depression. J Psychiatr Res 2012; 46:1643-1649
148. Versace A, Almeida JR, Quevedo K, et al: Right orbitofrontal cor-ticolimbic and left corticocortical white matter connectivity dif-ferentiatebipolar and unipolar depression.Biol Psychiatry 2010; 68: 560-567
149. Grotegerd D, Suslow T, Bauer J, et al: Discriminating unipolar and bipolar depression by means of fMRI and pattern classification: a pilot study. Eur Arch Psychiatry Clin Neurosci 2013; 263:119-131
150. Cardoso de Almeida JR, Phillips ML: Distinguishing between unipolar depression and bipolar depression: current and future clinical and neuroimaging perspectives. Biol Psychiatry 2013; 73: 111-118
151. Briceño EM, Weisenbach SL, Rapport LJ, et al: Shifted inferior frontallateralityinwomenwithmajordepressivedisorderisrelated to emotion-processing deficits. Psychol Med 2013; 43:1433-1445
152. Davidson RJ, Shackman AJ, Maxwell JS: Asymmetries in face and brain related to emotion. Trends Cogn Sci 2004; 8:389-391
153. Surguladze SA, Young AW, Senior C, et al: Recognition accuracyand response bias to happy and sad facial expressions in patients with major depression. Neuropsychology 2004; 18:212-218
154. Fournier JC, Keener MT, Mullin BC, et al: Heterogeneity of amygdala response in major depressive disorder: the impact of lifetime subthreshold mania. Psychol Med 2013; 43:293-302
155. Kahnt T, Heinzle J, Park SQ, et al: The neural code of reward anticipation in human orbitofrontal cortex. Proc Natl Acad Sci USA 2010; 107:6010-6015
156. Rolls ET, Grabenhorst F: The orbitofrontal cortex and beyond: from affect to decision-making. Prog Neurobiol 2008; 86:216-244
157. Dichter GS, Kozink RV, McClernon FJ, et al: Remitted major depression is characterized by reward network hyperactivation during reward anticipation and hypoactivation during reward outcomes. J Affect Disord 2012; 136:1126-1134
158. Urosevic S, Abramson LY, Harmon-Jones E, et al: Dysregulation of the behavioral approach system (BAS) in bipolar spectrum disorders: review of theory and evidence. Clin Psychol Rev 2008; 28: 1188-1205
159. Little JT, Ketter TA, Kimbrell TA, et al: Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression. Biol Psychiatry 2005; 57:220-228
160. Chen CH, Ridler K, Suckling J, et al: Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment. Biol Psychiatry 2007; 62:407-414
161. Salvadore G, Cornwell BR, Colon-Rosario V, et al: Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry 2009; 65:289-295
162. Roy M, Harvey PO, Berlim MT, et al: Medial prefrontal cortex activity during memory encoding of pictures and its relation to symptomatic improvement after citalopram treatment in patients with major depression. J Psychiatry Neurosci 2010; 35:152-162
163. Siegle GJ, Carter CS, Thase ME: Use of fMRI to predict recovery from unipolar depression with cognitive behavior therapy. Am J Psychiatry 2006; 163:735-738
164. Fu CH, Williams SC, Cleare AJ, et al: Neural responses to sad facial expressions in major depression following cognitive behavioral therapy. Biol Psychiatry 2008; 64:505-512
165. Canli T, Cooney RE, Goldin P, et al: Amygdala reactivity to emotional faces predicts improvement in major depression. Neuro-report 2005; 16:1267-1270
166. Langenecker SA, Kennedy SE, Guidotti LM, et al: Frontal and limbic activation during inhibitory control predicts treatment response in major depressive disorder. Biol Psychiatry 2007; 62:1272-1280
167. Walsh ND, Williams SC, Brammer MJ, et al: A longitudinal functional magnetic resonance imaging study of verbal working memory in depression after antidepressant therapy. Biol Psychiatry 2007; 62: 1236-1243
168. Light SN, Heller AS, Johnstone T, et al: Reduced right ventrolateral prefrontal cortex activity while inhibiting positive affect is associated with improvement in hedonic capacity after 8 weeks of antidepressant treatment in major depressive disorder. Biol Psychiatry 2011; 70:962-968
169. Forbes EE, Olino TM, Ryan ND, et al: Reward-relatedbrain function as a predictor of treatment response in adolescents with major depressive disorder. Cogn Affect Behav Neurosci 2010; 10:107-118
170. Costafreda SG, Chu C, Ashburner J, et al: Prognostic and diagnostic potential of the structural neuroanatomy of depression. PLoS ONE 2009; 4:e6353
171. MacQueen GM: Magnetic resonance imaging and prediction of outcome in patients with major depressive disorder. J Psychiatry Neurosci 2009; 34:343-349
172. Taylor WD, Kuchibhatla M, Payne ME, et al: Frontal white matter anisotropy and antidepressant remission in late-life depression. PLoS ONE 2008; 3:e3267
173. Lui S, Parkes LM, Huang X, et al: Depressive disorders: focally altered cerebral perfusion measured with arterial spin-labeling MR imaging. Radiology 2009; 251:476-484
174. McGrath CL, Kelley ME, Holtzheimer PE, et al: Toward a neuro-imaging treatment selection biomarker for major depressive disorder. JAMA Psychiatry 2013; 70:821-829
175. Holtzheimer PE, Kelley ME, Gross RE, et al: Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression. Arch Gen Psychiatry 2012; 69:150-158
176. Davidson RJ, Irwin W, Anderle MJ, et al: The neural substrates of affective processing in depressed patients treated with venlafaxine. Am J Psychiatry 2003; 160:64-75
177. Mayberg HS, Silva JA, Brannan SK, et al: The functional neuroanatomy of the placebo effect. Am J Psychiatry 2002; 159:728-737
178. Williams LM, Rush AJ, Koslow SH, et al: International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol. Trials 2011; 12:4
179. Trivedi MH, McGrath PJ, Fava M, et al: Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC): rationale and design. J Psychiatr Res (in press)
180. Vosslamber S, van Baarsen LG, Verweij CL: Pharmacogenomics of IFN-beta in multiple sclerosis: towards a personalized medicine approach. Pharmacogenomics 2009; 10:97-108
181. Lee AY, Raya AK, Kymes SM, et al: Pharmacogeneticsofcomplement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 2009; 93:610-613
182. Lima JJ, Blake KV, Tantisira KG, et al: Pharmacogeneticsofasthma. Curr Opin Pulm Med 2009; 15:57-62
183. Ouzounian M, Lee DS, Gramolini AO, et al: Predict, prevent, and personalize: genomic and proteomic approaches to cardiovascular medicine. Can J Cardiol 2007;23(suppl A):28A-33A
184. Dowsett M, Dunbier AK: Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 2008; 14:8019-8026